Age-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status After Acute and Chronic Application.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Cardiovascular Diseases
- Sponsor
- Heinrich-Heine University, Duesseldorf
- Enrollment
- 44
- Locations
- 1
- Primary Endpoint
- Endothelial function
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Epidemiological studies suggest that certain foods rich in flavanols, including cocoa products, red wine, and tea, are associated with decreased cardiovascular mortality and morbidity. Dietary interventional studies have corroborated this finding and showed that flavanols can acutely and after sustained ingestion improve surrogate markers of cardiovascular risk including endothelial function. Endothelial dysfunction is the key event in the development and progression of cardiovascular disease. Aging is the major non-modifiable cardiovascular risk factor associated with progressive decline in endothelial function, vascular stiffening and increase in blood pressure. We hypothesize that flavanols can counteract age-dependent vascular changes by interacting with key mechanisms, most prominently endothelial function.
Investigators
Klinik für Kardiologie, Pneumologie und Angiologie
Klinik für Kardiologie, Pneumologie und Angiologie
Heinrich-Heine University, Duesseldorf
Eligibility Criteria
Inclusion Criteria
- •healthy male participants between 18-35 years
- •healthy male participants between 50-80 years
Exclusion Criteria
- •acute inflammation
- •cardiac arrhythmia
- •renal failure
- •heart failure (NYHA II-IV)
- •diabetes mellitus
- •CRP \> 1 mg/dl
- •malignant disease
Outcomes
Primary Outcomes
Endothelial function
Time Frame: change in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14
Flow mediated dilatation (FMD)
Secondary Outcomes
- Ambulatory blood pressure(blood pressure at day 0 and at day 14)
- Pulse wave velocity(14 days)
- Heart rate(14 days)
- Plasma flavanol metabolites(analysis of metabolites between first treatment at day 0 and after last treatment at day 14)
- Erythrocyte deformability(14 days)
- NO bioavailability(14 days)
- Microvascular function(14 days)
- Augmentation index(14 days)